Comparative Pharmacology
Head-to-head clinical analysis: OXACILLIN SODIUM versus POLYCILLIN PRB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXACILLIN SODIUM versus POLYCILLIN PRB.
OXACILLIN SODIUM vs POLYCILLIN-PRB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxacillin is a penicillinase-resistant beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking the transpeptidation step in peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamase.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
1-2 grams IV every 4-6 hours.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
None Documented
None Documented
0.3-0.8 hours in adults with normal renal function; prolonged to 1-2 hours in neonates and 2-5 hours in patients with severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
Renal (70-80% unchanged by tubular secretion and glomerular filtration); biliary (minor, approximately 10%)
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic